Burkitt Lymphoma — Trials

Burkitt Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

247 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 27
Ph III recruiting: 0
Growth YoY: —
Industry share: 20%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07819396	Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome	not yet recruiting	Phase 2	52	Fred Hutchinson Cancer CenterOTHER	1	Sep 14, 2026	clinicaltrials
NCT07724457	Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma	not yet recruiting	Phase 2 / Phase 3	271	National Cancer Institute (NCI)NIH